MOD-GRF (1-29)
Performance, Muscle Building
In short
- This is the same molecule as CJC-1295 without DAC — modified GHRH(1-29), sold under a different name.
- The naming confusion in this market is genuine and worth understanding: "CJC-1295" originally referred to the DAC version, and the non-DAC version acquired the same name by association.
- Half-life around 30 minutes, producing a sharp GH pulse rather than sustained elevation.
- Acts on the GHRH receptor, distinct from the ghrelin receptor targeted by the GHRPs — which is the basis for combining them.
- Prohibited at all times in sport under WADA class S2.
Structure
A 29-amino-acid modified GHRH analogue. PubChem has no entry under this research-market name, and peptides and proteins of this size are represented by sequence rather than a small-molecule structure diagram.
How it works
MOD-GRF (1-29) is GHRH(1-29) — the shortest fragment retaining full GHRH activity — with four amino acid substitutions that resist enzymatic degradation, principally by DPP-4.
It binds the GHRH receptor on anterior pituitary somatotrophs and stimulates GH synthesis and release. Because it lacks the drug affinity complex, it does not bind albumin and clears within roughly half an hour, producing a discrete pulse.
See the CJC-1295 no DAC entry — these are the same compound, and the arguments about pulsatile versus sustained GH elevation apply identically.
What the research shows
GHRH analogues reliably raise GH and IGF-1 in humans; this is established at the class level and demonstrated definitively by tesamorelin, the approved member of the class.
For this specific research-market product there is no controlled human outcome data. Body composition and recovery claims are anecdotal.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — GHRH(1-29) analogues, GH stimulation studies | Microgram-per-kilogram intravenous doses produce dose-dependent GH release | intravenous | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported, typically alongside a GHRP | 100 µg, one to three times daily | subcutaneous |
No published human pharmacokinetic study establishes a dose, interval, or duration for this compound. Community figures below have no trial behind them and are reports of practice, not evidence. The 100 µg figure is a community convention rather than a studied dose. The practical point specific to this compound is verifying which form you have — DAC and non-DAC differ in half-life by roughly two orders of magnitude and are frequently mislabelled.
Handling and storage
Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. The powder is comparatively stable; once reconstituted it is refrigerated and used within weeks. Track the date you reconstitute each vial — the Inventory section does this, and it is the difference between knowing a vial is three weeks old and guessing.
Subcutaneous injection. The short half-life makes timing consequential: doses are typically taken away from food, since elevated glucose and insulin blunt GH release, and often before sleep to coincide with the natural nocturnal pulse.
Side effects
Reported: injection-site reactions, flushing, a head-rush shortly after injection, and water retention.
Class effects of raising GH apply — joint discomfort, carpal tunnel symptoms, and reduced insulin sensitivity, though these are more associated with sustained elevation than with brief pulses.
No long-term human safety data exists for this compound as sold.
Combinations
The canonical pairing is with a GHRP such as ipamorelin. GHRH and ghrelin receptors are separate, and the combination produces a larger GH pulse than either alone — a synergy documented for the drug classes in endocrinology literature, though not for these specific research-market products.
Research status
The GHRH(1-29) literature is solid at class level and underpins tesamorelin's approval. The specific modified analogue sold under this name has no clinical trial of its own.
Legal status
Not approved in any jurisdiction. Sold for research use only. GHRH analogues appear on the FDA list of substances presenting significant risks for compounding.
WADA status
PROHIBITED AT ALL TIMES under WADA class S2 — growth hormone secretagogues, their releasing factors and mimetics are explicitly named. Any tested athlete should treat this as an anti-doping violation.
Conclusion
MOD-GRF (1-29) and CJC-1295 without DAC are the same thing. If you are comparing vendors selling both, you are comparing labels rather than molecules.
The mechanism is well understood and the specific product is not characterised. Knowing whether you hold the DAC or non-DAC form matters far more than the dose.
Sources
Track your own MOD-GRF (1-29) protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.